6323-14-4

Basic information

• Product Name: 1-(4-chlorophenyl)-4-(3-chloropropyl)piperazine
• CAS NO: 6323-14-4
• Molecular Formula: C₁₃H₁₈Cl₂N₂
• Molecular Weight: 273.2014
• Mol File: 6323-14-4.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 395.7°C at 760 mmHg
• Flash Point: 193.1°C
• Density: 1.186g/cm³
• Vapor Pressure: 1.8E-06mmHg at 25°C
• Refractive Index: 1.553
• CAS DataBase Reference: 1-(4-chlorophenyl)-4-(3-chloropropyl)piperazine(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(4-chlorophenyl)-4-(3-chloropropyl)piperazine(6323-14-4)
• EPA Substance Registry System: 1-(4-chlorophenyl)-4-(3-chloropropyl)piperazine(6323-14-4)

Safety Data

• Hazardous Substances Data: 6323-14-4(Hazardous Substances Data)

Usage

Chemical structure

The compound consists of a piperazine ring with a 4-chlorophenyl group and a 3-chloropropyl group attached.

Class of compounds

It belongs to the piperazine class of compounds.

Pharmaceutical use

Piperazine compounds are commonly used in the pharmaceutical industry.

Research applications

The compound has been studied for its potential use in various therapeutic applications.

Antidepressant and anxiolytic potential

It has been investigated for its potential use as an antidepressant and anxiolytic.

Serotonin and norepinephrine reuptake inhibition

The compound has been studied for its potential to act as a serotonin and norepinephrine reuptake inhibitor, which could make it useful in the treatment of depression and anxiety disorders.

Antipsychotic potential

It has been studied for its potential as an antipsychotic.

Antiemetic potential

The compound has been investigated for its potential as an antiemetic.

Ongoing research

1-(4-chlorophenyl)-4-(3-chloropropyl)piperazine continues to be the subject of ongoing research due to its promising therapeutic applications.

Upstream product

• 38212-33-8 4-(4-chlorophenyl) piperazine 
• 109-70-6 1.3-chlorobromopropane 
• 13078-12-1 1-(4-chlorophenyl)piperazine hydrochloride 

Downstream Products

• 84344-61-6 1-(4-nitrophenoxy)-3-1-(N⁴-(4-chlorophenyl)piperazinyl)>propane 
• 84344-62-7 3-{3-[4-(4-Chloro-phenyl)-piperazin-1-yl]-propoxy}-benzaldehyde 
• 174519-58-5 N¹-{3-[4-(4-Chloro-phenyl)-piperazin-1-yl]-propyl}-ethane-1,2-diamine 
• 223525-89-1 1-[4-(4-chlorophenyl)piperazin-1-yl]-3-[2-oxopiperidin-1-yl]propane 
• 115098-04-9 1-[4-(2-chloro-phenyl)-piperazino]-3-[4-(4-chloro-phenyl)-piperazino]-propane 
• 6320-27-0 1-[4-(4-chloro-phenyl)-piperazino]-3-(4-o-tolyl-piperazino)-propane 
• 115098-03-8 1-[4-(3-chloro-phenyl)-piperazino]-3-[4-(4-chloro-phenyl)-piperazino]-propane 
• 114694-62-1 1-[4-(4-chloro-phenyl)-piperazino]-3-(4-p-tolyl-piperazino)-propane 
• 6320-29-2 1-[4-(4-chloro-phenyl)-piperazino]-3-(4-m-tolyl-piperazino)-propane 
• 112551-52-7 1-[4-(4-chloro-phenyl)-piperazino]-3-(4-phenyl-piperazino)-propane 

Relevant articles and documents

Design, synthesis, and biological evaluation of arylpiperazine-benzylpiperidines with dual serotonin and norepinephrine reuptake inhibitory activities

The limitations of established serotonin (5-hydroxytryptamine, 5-HT) and norepinephrine (NE) reuptake inhibitors necessitate the development of safer and more effective therapeutic agents. Based on the structures of 4-benzylpiperidine carboxamides and trazodone, arylpiperazine-benzylpiperidines with chemical scaffolds different from those of marketed drugs were designed, synthesized, and evaluated for their neurotransmitter reuptake inhibitory activities. The majority of the synthesized compounds showed greater NE than 5-HT reuptake inhibition. The activities were even greater than those of the standard drug, venlafaxine hydrochloride were. The derivatives with a three-carbon linker showed better activities than the derivatives with a two-carbon linker. Among the newly synthesized compounds, 2d exhibited the strongest reuptake inhibition of the neurotransmitters (IC50 = 0.38 μM for NE and 1.18 μM for 5-HT). The biological activity data demonstrate that arylpiperazine-benzylpiperidines have the potential to be developed as a new class of therapeutic agents to treat neuropsychiatric and neurodegenerative disorders.

Synthesis of new 1,2,3-benzotriazin-4-one-arylpiperazine derivatives as 5-HT(1A) serotonin receptor ligands

A series of novel 1,2,3-benzotriazin-4-one derivatives was prepared and evaluated as ligands for 5-HT receptors. Radioligand binding assays proved that the majority of the novel compounds behaved as good to excellent ligands at the 5-HT(1A) receptor, some of which were selective with respect 5-HT(2A) and 5-HT(2C) receptors. Six analogues (1a, 2a, 2b, 2c, 2e and 2i) were selected and further evaluated for their binding affinities on D1, D2 dopaminergic and α1-, α2-adrenergic receptors. A o-OCH3 derivative (2e) bound at 5-HT(1A) sites with subnanomolar affinity (IC50=0.059 nM) and shows high selectivity over all considered receptors and may offer a new lead for the development of therapeutically efficacious agents. Copyright (C) 2000 Elsevier Science Ltd.

Synthesis and trazodone-like pharmacological profile of 1- and 2--propyl>benzotriazoles

A series of 1- and 2--propyl>benzotriazoles were prepared and evaluated for their trazodone-like pharmacological profile; as preliminary pharmacological screening, the compounds were tested for their antiserotonergic, antiadrenergic and antihistaminic in vitro activity as well as for their analgesic in vivo action.Structure-activity relationships showed that among the synthesized compounds, the analogues bearing on the 4-piperazine nitrogen either an unsubstituted phenyl ring or a 2- or 3-chloro phenyl moiety show a pharmacological profilesimilar to that of the antidepressant trazodone. benzotriazoles / antiserotonergic / antiadrenergic / antihistaminic/ analgesic